Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daphne W Bell

Showing results (11-20 of 61) with videos related to

Pageof 7
Sort By:
Current Opinion in Genetics & Development|January 27, 2015
The mutational landscape of endometrial cancerBo Hong, Matthieu Le Gallo, Daphne W Bell
Advances in Experimental Medicine and Biology|December 3, 2016
Next-Generation SequencingMatthieu Le Gallo, Fred Lozy, Daphne W Bell
Cancer|April 19, 2021
High-risk endometrial cancer proteomic profiling reveals that FBXW7 mutation alters L1CAM and TGM2 protein levelsMary Ellen Urick, Eun-Jeong Yu, Daphne W Bell
Cancer|July 29, 2021
Reply to FBXW7, L1CAM, and TGM2 in endometrial cancerMary Ellen Urick, Eun-Jeong Yu, Daphne W Bell
Science (New York, N.Y.)|July 31, 2004
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathwaysRaffaella Sordella, Daphne W Bell, Daniel A Haber, et al.
Nature Reviews. Cancer|February 24, 2007
Epidermal growth factor receptor mutations in lung cancerSreenath V Sharma, Daphne W Bell, Jeffrey Settleman, et al.
Cancer Research|May 23, 2002
Selective loss of heterozygosity in multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2Daphne W Bell, John Erban, Dennis C Sgroi, et al.
Cancer Medicine|March 15, 2025
Proteomic Changes Associated With Endogenous FBXW7 Mutations in Moderately Differentiated Endometrial Cancer Cells Include Increased TROP2 and Galectin-3 LevelsMary Ellen Urick, Suresh Kumar Chalapareddy, Eun-Jeong Yu, et al.
Advances in Experimental Medicine and Biology|December 3, 2016
Epidemiology of Endometrial Carcinoma: Etiologic Importance of Hormonal and Metabolic InfluencesAshley S Felix, Hannah P Yang, Daphne W Bell, et al.
The New England Journal of Medicine|April 22, 2005
Pulmonary adenocarcinomas with mutant epidermal growth factor receptorsMarkus J Riemenschneider, Daphne W Bell, Daniel A Haber, et al.
Pageof 7

Showing results (11-20 of 61) with videos related to

Sort By:
Pageof 7
Current Opinion in Genetics & Development|January 27, 2015
The mutational landscape of endometrial cancerBo Hong, Matthieu Le Gallo, Daphne W Bell
Advances in Experimental Medicine and Biology|December 3, 2016
Next-Generation SequencingMatthieu Le Gallo, Fred Lozy, Daphne W Bell
Cancer|April 19, 2021
High-risk endometrial cancer proteomic profiling reveals that FBXW7 mutation alters L1CAM and TGM2 protein levelsMary Ellen Urick, Eun-Jeong Yu, Daphne W Bell
Cancer|July 29, 2021
Reply to FBXW7, L1CAM, and TGM2 in endometrial cancerMary Ellen Urick, Eun-Jeong Yu, Daphne W Bell
Science (New York, N.Y.)|July 31, 2004
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathwaysRaffaella Sordella, Daphne W Bell, Daniel A Haber, et al.
Nature Reviews. Cancer|February 24, 2007
Epidermal growth factor receptor mutations in lung cancerSreenath V Sharma, Daphne W Bell, Jeffrey Settleman, et al.
Cancer Research|May 23, 2002
Selective loss of heterozygosity in multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2Daphne W Bell, John Erban, Dennis C Sgroi, et al.
Cancer Medicine|March 15, 2025
Proteomic Changes Associated With Endogenous FBXW7 Mutations in Moderately Differentiated Endometrial Cancer Cells Include Increased TROP2 and Galectin-3 LevelsMary Ellen Urick, Suresh Kumar Chalapareddy, Eun-Jeong Yu, et al.
Advances in Experimental Medicine and Biology|December 3, 2016
Epidemiology of Endometrial Carcinoma: Etiologic Importance of Hormonal and Metabolic InfluencesAshley S Felix, Hannah P Yang, Daphne W Bell, et al.
The New England Journal of Medicine|April 22, 2005
Pulmonary adenocarcinomas with mutant epidermal growth factor receptorsMarkus J Riemenschneider, Daphne W Bell, Daniel A Haber, et al.
Pageof 7